Ahmed, Mahmoud Salama https://orcid.org/0000-0002-5600-4698
Nguyen, Ngoc Uyen Nhi https://orcid.org/0000-0003-0694-3176
Nakada, Yuji
Hsu, Ching-Cheng https://orcid.org/0000-0002-8804-6171
Farag, Ayman
Lam, Nicholas T. https://orcid.org/0000-0002-9446-7378
Wang, Ping
Thet, Suwannee
Menendez-Montes, Ivan https://orcid.org/0000-0001-5252-9502
Elhelaly, Waleed M.
Lou, Xi
Secco, Ilaria https://orcid.org/0000-0002-3920-7565
Tomczyk, Mateusz https://orcid.org/0000-0001-9322-748X
Zentilin, Lorena
Pei, Jimin
Cui, Miao
Dos Santos, Matthieu
Liu, Xiaoye
Liu, Yan
Zaha, David
Walcott, Gregory
Tomchick, Diana R. https://orcid.org/0000-0002-7529-4643
Xing, Chao https://orcid.org/0000-0002-1838-0502
Zhang, Cheng Cheng https://orcid.org/0000-0003-4763-3887
Grishin, Nick V.
Giacca, Mauro https://orcid.org/0000-0003-2927-7225
Zhang, Jianyi https://orcid.org/0000-0002-3955-6554
Sadek, Hesham A. https://orcid.org/0000-0002-4745-366X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (1P01HL160476-01A1)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R35 HL166563-01)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NIH P01HL160488)
Fondation Leducq (Redox Leducq)
Foundation for the National Institutes of Health (R01GM119336)
American Heart Association (856552)
American Heart Association (19POST34450039)
Article History
Received: 10 November 2023
Accepted: 6 February 2024
First Online: 11 March 2024
Competing interests
: M.G. is founder, consultant, member of the board and equity holder in Forcefield Therapeutics, Heqet Therapeutics and Purespring Therapeutics. All other authors declare no competing interests.